Skip to main content
Top
Published in: Dermatology and Therapy 4/2022

Open Access 01-04-2022 | Alopecia | Review

Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework

Authors: Brett A. King, Maryanne M. Senna, Manabu Ohyama, Antonella Tosti, Rodney D. Sinclair, Susan Ball, Justin M. Ko, Marc Glashofer, Rodrigo Pirmez, Jerry Shapiro

Published in: Dermatology and Therapy | Issue 4/2022

Login to get access

Abstract

Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. As a clinically heterogeneous disease, various classification systems have evolved for defining its severity. In this high-level review of the literature, we discuss the traditional classification systems for AA severity and their strengths and weaknesses. Most recent classifications have focused on the extent of scalp hair loss as a defining feature, but additional clinical aspects of the disease, including location, pattern, and duration of hair loss as well as impact on the patient’s quality of life, are also relevant. These various components have typically been used unidimensionally to classify patients. We propose a multidimensional framework to define AA severity that incorporates multiple patient- and illness-related domains. Using such a framework, dermatologists may better assess the severity of the disease for the individual patient beyond the extent of hair loss.
Literature
1.
go back to reference Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78:1–12.CrossRefPubMed Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78:1–12.CrossRefPubMed
2.
go back to reference Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67:891–7.CrossRefPubMedPubMedCentral Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67:891–7.CrossRefPubMedPubMedCentral
3.
go back to reference Besnier E, Brocq L, Jacquet L. La pratique dermatologique. In la pratique dermatologique,1902. p. 920. Besnier E, Brocq L, Jacquet L. La pratique dermatologique. In la pratique dermatologique,1902. p. 920.
4.
go back to reference Ikeda T. A new classification of alopecia areata. Dermatology. 1965;131:421–45.CrossRef Ikeda T. A new classification of alopecia areata. Dermatology. 1965;131:421–45.CrossRef
5.
go back to reference Sharma VK, Muralidhar S, Kumar B. Reappraisal of Ikeda’s classification of alopecia areata: analysis of 356 cases from Chandigarh, India. J Dermatol. 1998;25:108–11.CrossRefPubMed Sharma VK, Muralidhar S, Kumar B. Reappraisal of Ikeda’s classification of alopecia areata: analysis of 356 cases from Chandigarh, India. J Dermatol. 1998;25:108–11.CrossRefPubMed
6.
go back to reference Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines--part ii. National alopecia areata foundation. J Am Acad Dermatol. 2004;51:440–447. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines--part ii. National alopecia areata foundation. J Am Acad Dermatol. 2004;51:440–447.
7.
go back to reference Olsen EA, Canfield D. Salt II: a new take on the severity of alopecia tool (salt) for determining percentage scalp hair loss. J Am Acad Dermatol. 2016;75:1268–70.CrossRefPubMed Olsen EA, Canfield D. Salt II: a new take on the severity of alopecia tool (salt) for determining percentage scalp hair loss. J Am Acad Dermatol. 2016;75:1268–70.CrossRefPubMed
8.
go back to reference Jang YH, Moon SY, Lee WJ, Lee SJ, Lee WK, Park BC, et al. Alopecia areata progression index, a scoring system for evaluating overall hair loss activity in alopecia areata patients with pigmented hair: a development and reliability assessment. Dermatology. 2016;232:143–9.CrossRefPubMed Jang YH, Moon SY, Lee WJ, Lee SJ, Lee WK, Park BC, et al. Alopecia areata progression index, a scoring system for evaluating overall hair loss activity in alopecia areata patients with pigmented hair: a development and reliability assessment. Dermatology. 2016;232:143–9.CrossRefPubMed
9.
go back to reference Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183:702–9.CrossRefPubMedPubMedCentral Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183:702–9.CrossRefPubMedPubMedCentral
10.
go back to reference Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83:123–30.CrossRefPubMed Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83:123–30.CrossRefPubMed
11.
go back to reference Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. J Am Acad Dermatol. 2020. Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. J Am Acad Dermatol. 2020.
12.
go back to reference Liu LY, King BA, Ko JM. Eyebrows are important in the treatment of alopecia areata. J Investig Dermatol Symp Proc. 2020;20:S37-s40.CrossRefPubMed Liu LY, King BA, Ko JM. Eyebrows are important in the treatment of alopecia areata. J Investig Dermatol Symp Proc. 2020;20:S37-s40.CrossRefPubMed
13.
go back to reference Wambier CG, King BA. Rethinking the classification of alopecia areata. J Am Acad Dermatol. 2019;80:e45. Wambier CG, King BA. Rethinking the classification of alopecia areata. J Am Acad Dermatol. 2019;80:e45.
14.
go back to reference Roest YBM, van Middendorp HT, Evers AWM, van de Kerkhof PCM, Pasch MC. Nail involvement in alopecia areata: a questionnaire-based survey on clinical signs, impact on quality of life and review of the literature. Acta Derm Venereol. 2018;98:212–7.CrossRefPubMed Roest YBM, van Middendorp HT, Evers AWM, van de Kerkhof PCM, Pasch MC. Nail involvement in alopecia areata: a questionnaire-based survey on clinical signs, impact on quality of life and review of the literature. Acta Derm Venereol. 2018;98:212–7.CrossRefPubMed
15.
go back to reference Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60:163–70.CrossRefPubMed Cranwell WC, Lai VW, Photiou L, Meah N, Wall D, Rathnayake D, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60:163–70.CrossRefPubMed
16.
go back to reference Aldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, et al. “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” A qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4:76.CrossRefPubMedPubMedCentral Aldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, et al. “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” A qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4:76.CrossRefPubMedPubMedCentral
17.
go back to reference Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: Results of the HOME VII consensus meeting. Br J Dermatol. 2021;185:139–46.CrossRefPubMedPubMedCentral Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: Results of the HOME VII consensus meeting. Br J Dermatol. 2021;185:139–46.CrossRefPubMedPubMedCentral
18.
go back to reference Chren MM. The skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30:231–236, xiii. Chren MM. The skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30:231–236, xiii.
19.
go back to reference Mendoza TR, Osei J, Duvic M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc. 2018;19:S41-s46.CrossRefPubMed Mendoza TR, Osei J, Duvic M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc. 2018;19:S41-s46.CrossRefPubMed
20.
go back to reference Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Measurement properties of the hospital anxiety and depression scale used in atopic dermatitis in adults. J Invest Dermatol. 2019;139:1388–91.CrossRefPubMed Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Measurement properties of the hospital anxiety and depression scale used in atopic dermatitis in adults. J Invest Dermatol. 2019;139:1388–91.CrossRefPubMed
21.
go back to reference Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed
22.
go back to reference US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. The voice of the patient: a series of reports from the U.S. Food and Drug Administration's (FDA's) patient‐focused drug development initiative. Alopecia areata. 2018. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. The voice of the patient: a series of reports from the U.S. Food and Drug Administration's (FDA's) patient‐focused drug development initiative. Alopecia areata. 2018.
23.
go back to reference King BA, Mesinkovska NA, Craiglow B, Kindred C, Ko J, McMichael A, et al. Development of the alopecia areata scale for clinical use: results of an academic–industry collaborative effort. J Am Acad Dermatol. 2021. King BA, Mesinkovska NA, Craiglow B, Kindred C, Ko J, McMichael A, et al. Development of the alopecia areata scale for clinical use: results of an academic–industry collaborative effort. J Am Acad Dermatol. 2021.
24.
go back to reference Senna MM, Ko J, Glashofer M, Walker C, Ball S, Heredia E, et al. Predictors of quality of life in patients with alopecia areata. Manuscript under review, 2021. Senna MM, Ko J, Glashofer M, Walker C, Ball S, Heredia E, et al. Predictors of quality of life in patients with alopecia areata. Manuscript under review, 2021.
Metadata
Title
Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework
Authors
Brett A. King
Maryanne M. Senna
Manabu Ohyama
Antonella Tosti
Rodney D. Sinclair
Susan Ball
Justin M. Ko
Marc Glashofer
Rodrigo Pirmez
Jerry Shapiro
Publication date
01-04-2022
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 4/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-022-00711-3

Other articles of this Issue 4/2022

Dermatology and Therapy 4/2022 Go to the issue